Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

Stopped Study was stopped due to negative preliminary analysis, slow recruitment (105 patients over 2,5 years), lack of funding, need for more centers, and the changing treatment landscape (approval of ICIs in combination with other cancer treatments).

Conditions

• Cancer
• Immune-related Adverse Event
• Cardiac Abnormalities, Variable
• Immune Checkpoint Inhibitor-Related Myocarditis
• Diastolic Dysfunction
• Atherosclerosis
• Cardiotoxicity

Interventions

• PROCEDURE: Cardiology consultation
• DIAGNOSTIC_TEST: Chest Computed Tomography (CT) without contrast
• PROCEDURE: Non-invasive endothelial function tests
• PROCEDURE: Electrocardiogram
• DIAGNOSTIC_TEST: Extra serum sample (7.5 mL)

Sponsor

Algemeen Ziekenhuis Maria Middelares